The Psychoimmunology of Lyme/Tick-Borne Diseases and its Association with Neuropsychiatric Symptoms

Robert C. Bransfield*

225 Highway #35, Red Bank, NJ 07701, USA

Abstract: Disease progression of neuropsychiatric symptoms in Lyme/tick-borne diseases can be better understood by greater attention to psychoimmunology. Although there are multiple contributors that provoke and weaken the immune system, infections and persistent infections are significant causes of pathological immune reactions. Immune mediated effects are a significant contributor to the pathophysiological processes and disease progression. These immune effects include persistent inflammation with cytokine effects and molecular mimicry and both of these mechanisms may be present at the same time in persistent infections. Sickness syndrome associated with interferon treatment and autoimmune limbic encephalopathies are models to understand inflammatory and molecular mimicry effects upon neuropsychiatric symptoms. Progressive inflammatory reactions have been proposed as a model to explain disease progression in depression, psychosis, dementia, epilepsy, autism and other mental illnesses and pathophysiological changes have been associated with oxidative stress, excitotoxicity, changes in homocysteine metabolism and altered tryptophan catabolism. Lyme disease has been associated with the proinflammatory cytokines IL-6, IL-8, IL-12, IL-18 and interferon-gamma, the chemokines CXCL12 and CXCL13 and increased levels proinflammatory lipoproteins. Borrelia burgdorferi surface glycolipids and flagella antibodies appear to elicit anti-neuronal antibodies and anti-neuronal antibodies and Borrelia burgdorferi lipoproteins can disseminate from the periphery to inflame the brain. Autism spectrum disorders associated with Lyme/tick-borne diseases may be mediated by a combination of inflammatory and molecular mimicry mechanisms. Greater interaction is needed between infectious disease specialists, immunologists and psychiatrists to benefit from this awareness and to further understand these mechanisms.

Keywords: Immune, inflammation, Lyme, mental, psychiatric, tick-borne.

INTRODUCTION

There are different degrees of evidence that infections and the immune reactions to them can cause degenerative neurological disease, mental illness, cognitive decline, developmental disabilities, personality changes and violence and the pathophysiology needs better clarification [1-7]. Disease can result from an interaction of predisposing and precipitating factors [5]. When diseases are associated with infection, the infection is followed by immune and other reactions that can lead to a pathophysiological process resulting in dysfunction leading to symptoms and syndromes of dysfunction [5]. Ineffective treatment then can result in further disease progression [8].

Understanding the interaction between the immune system and nervous systems is critical however psychiatrists have little training and experience in immunology and immunologists have little training and experience dealing with psychiatry. However, the brain and immune systems have many similarities—both defend against threats by shifting allocation of resources as environments change; both have intracellular transmitters, receptors and feedback capability; there are similarities between the gut and immune barrier and the bold brain barrier (BBB); both have innate and learned capabilities and in both cases failures to shift from innate to learned responses result in pathology. [9] The brain and immune systems both switches back and forth, eliminating one threat then recovering before responding to the next threat.

MICROBES AND IMMUNE REACTIONS

There are a number of environmental conditions that may provoke and/or weaken the immune system—infestations, cancer, allergens, stress, sleep deprivation, vaccinations, trauma, toxins, degenerative changes, molecular mimicry, low glutathione levels, increased oxidative stress, metal toxicity, elevated leptin levels and some medical treatments [10-13]. Microbial effects are a major consideration for impacting neuronal functioning [14]. Thousands of peer-reviewed journal articles demonstrate the causal association between infections and mental illness and over 250 peer-reviewed scientific articles demonstrate the causal association between Lyme/tick-borne disease and mental illness [15].

Bacterial infections are recognized to be associated with many autoimmune diseases involving chronic inflammation and demyelination [16]. Possible modes of pathogenic action of bacteria include cytokines, toll-like receptor signaling, the interaction of heat shock proteins with the immune system,
and nitric oxide. An auto-regulatory loop might exist in the interaction of bacteria with the host and in pathogenic signal processing [17]. Two common questions are whether trauma is directly from the infection or from the host’s immune or other reactions to the infection and another and whether symptoms in the central nervous system (CNS) are a result of infection within the CNS or whether the infection is outside the CNS but immune effects are causing CNS symptoms? Parasite effects include cytokine release, antibodies, inflammation and other cellular responses. Sickness syndrome is a useful model to differentiate the symptoms commonly associated inflammation from the symptoms mediated by other processes. Sickness syndrome is mediated by the proinflammatory cytokines cascade with effects from interleukin-1 (IL), IL-6, and tumor necrosis factor (TNF) [18]. Interferon treatment for Hepatitis C and other conditions is a good model for demonstrating inflammation mediated mental symptoms. Symptoms seen with interferon treatment include cognitive impairments, depression, anxiety, mania, irritability, impulsiveness, hostility, relapse of substance abuse and lassitude [19,20].

**DISEASE PROGRESSION**

It is recognized chronic infections cause chronic stress, sleep disorders, cognitive impairments and chronic fatigue. Sleep disorders are commonly associated with chronic inflammatory diseases and chronic stress-related disorders. The best studied in this regard are rheumatoid arthritis, fibromyalgia, chronic fatigue syndromes and Lyme disease [21-23]. The bidirectional communication between the brain and the immune system contribute to inflammatory mediated disrupted sleep quality and conversely [24]. Cytokines produced by cells of the immune and nervous systems (particularly IL-1-beta and TNF-alpha) regulate sleep, signal neuroendocrine, autonomic, limbic and cortical areas of the CNS to affect neural activity and modify behaviors, hormone release and autonomic function [23]. To demonstrate the association between inflammation, chronic fatigue and sleep disturbances it has been demonstrated that sleep restriction increases IL-6 and pain-related symptoms in healthy volunteers and impaired sleep correlates with impaired immune functioning [22, 24]. Growth hormone modulates adaptive immune response but growth hormone production is dependent upon the presence of delta sleep which is reduced in an inflammatory state [25]. Therefore, increasing delta sleep is therapeutic while disease progression is fostered by non-restorative sleep and is associated with fatigue, cognitive impairments, pain and emotional symptoms [26]. The consequences of both non-restorative sleep and associated chronic stress reactions contribute to perpetuating the disease process and are associated with—decreased regenerative functioning, compromised immunity, oxidative stress and decreased resistance to infectious disease [22,25,26].

**IMMUNE MEDIATED NEURODEGENERATIVE DISEASES**

Neurodegenerative diseases are a group of chronic, progressive disorders characterized by the gradual loss of neurons in discrete areas of the CNS. When neurodegenerative diseases are progressive uncontrolled inflammation drives disease progression [27]. Substantial evidence has documented a common inflammatory mechanism in various neurodegenerative diseases. It has been hypothesized that in the diseased CNS, interactions between damaged neurons and dysregulated, overactivated microglia create a vicious self-propagating cycle causing uncontrolled, prolonged inflammation that drives the chronic progression of neurodegenerative diseases [27]. There is evidence with depression, Alzheimer’s disease (AD), schizophrenia and epilepsy to support this position. A meta-analysis of cytokines in major depression including 24 studies reports significantly higher concentrations of the proinflammatory cytokines TNF-alpha and IL-6 in depressed subjects compared with control subjects [28]. A meta-analysis of cytokines in AD which reviewed 86 studies strengthens the clinical evidence that AD is accompanied by an inflammatory response with particularly higher peripheral concentrations of IL-6, TNF, IL-1, transforming growth factor, IL-12 and IL-18 and higher CSF concentrations of transforming growth factor [29]. Hundreds of studies of schizophrenic illness in adults have documented immunological abnormalities in these patients. First-episode psychosis in children is associated with evidence of increased inflammation. Increasing evidence now suggests that the glia, cerebral vasculature, and the BBB may be involved which support the inflammatory theory of schizophrenia that was formulated over a 100 years ago [30]. There is a rapidly growing body of evidence that supports the involvement of inflammatory mediators in epilepsy—released by brain cells and peripheral immune cells—in both the origin of individual seizures and the epileptogenic process. Aspects of brain inflammation and immunity were first described and subsequently, it was demonstrated how seizures cause inflammation, and whether such inflammation, in turn, influences the occurrence and severity of seizures, and seizure-related neuronal death [31].

Immune mediated mechanisms include inflammatory and autoimmune mechanisms. The inflammatory mediated effects associated with neurodegenerative disease and include oxidative stress, excitotoxicity, proinflammatory cytokine effects and altered tryptophan metabolism.

**INFLAMMATORY MEDIATED MECHANISMS**

Oxidative stress and oxygen free radicals or activated oxygen has been implicated in diverse environmental stresses and appears to be a common contributor in neurodegenerative diseases [32].

Excitotoxicity and inadequate remethylation leads to increased homocysteine levels which are excitotoxic [33]. Elevated C-reactive protein levels are linked to a decline in executive function and frontal lobe damage. There is an association between elevated levels of high-sensitivity C-reactive protein, an indicator of low-grade inflammation, and decline in executive function [34].

Proinflammatory cytokines include Interferon alpha, IL-1-beta and IL-6. Cytokine activation has been associated with psychiatric symptoms. For example, IL-6 is elevated in the cerebrospinal fluid of suicide attempters and is related to symptom severity, memory deficits and aggressiveness and
IL-1-beta is associated with self-inflicted aggressive behavior and fatigue [35-37]. Besides cytokine effects, IL-1 receptor activation by systemic lipopolysaccharides has been demonstrated as one of the mechanisms by which environmentally driven immune system activation can trigger despair-like behavior in an animal model [38].

It has been proposed that parasites improve their survival by evolving mechanisms to change host behavior and some of these mechanisms are mediated by changes in serotonin and other monoamines [39]. Inflammation provoked by parasites impacts the conversion of tryptophan into serotonin. The kynurenine pathway is a major route of L-tryptophan catabolism into serotonin with a number of metabolites that include—kynurenic acid which is an N-Methyl-D-aspartic acid (NMDA) antagonist (neuroprotective, unless excessive), quinolinic acid which is a NMDA agonist (neurotoxic). In an inflammatory state there is decreased serotonin & a shift to quinolinic acid rather than kynurenic acid. The enzyme indoleamine 2,3-dioxigenase (IDO), which converts tryptophan into kynurenine and which is stimulated by proinflammatory cytokines, is implicated in the development of interferon—induced depressive symptoms, first by decreasing the serotonin availability to the brain and second by the induction of the kynurenine pathway resulting in the production of neurotoxic metabolites. In persistent infections associated with persistent inflammation, chronic activation of TNF-alpha stimulates interferon-gamma, which overactivates IDO, the rate-limiting enzyme for catabolism of tryptophan in the brain. Overactivated IDO causes neurotoxicity, and immune suppression of cytotoxic T cells. Underactivation of IDO is known to cause autoimmune reactions, but it has recently been discovered that overactivated IDO causes autoimmune B cell antibody production [40]. CSF quinolinic acid is significantly elevated in a number of CNS infections including Borrelia burgdorferi (Bb), infection—dramatically in patients with CNS inflammation, less in encephalopathy. The presence of this known agonist of NMDA synaptic function; a receptor involved in learning, memory, and synaptic plasticity; may contribute to the neurologic and cognitive deficits seen in many Lyme disease patients [41].

INFLAMMATION AND LYME/TICK-BORNE DISEASES

Lyme disease, caused by the bacterium Bb, has been recognized to cause multi-systemic signs and symptoms, including peripheral and central nervous system disease. Some immune mediated pathophysiology seen in Lyme/Tick-Borne Diseases (LYD/TBD) is a Failure to Shift from Th1 to Th2. Persisting immune activation causes the cytokine storm in chronic Lyme. In these patients, the innate immune system is not turned off by a series of specific immune peptides. Specific genetic types are more prone to this phenomenon [42].

Increased levels of the proinflammatory cytokines IL-6, IL-8, IL-12, IL-18 and interferon γ and of the chemokines CXCL12 and CXCL13 have been reported in the CSF of patients with neurologic Lyme disease [43]. The magnitude of IL-6 in human serum and CSF has been shown to correlate with disease activity in neurologic Lyme disease [44]. Elevated levels of IL-6 can cause symptoms of fatigue and malaise, common to many infectious conditions as well as Lyme disease [45]. Borrelia species induce activation of IL-17 production. The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis CSF CXCL13 and can be used as a diagnostic marker for infection [46-48].

Bb spirochetes express lipoproteins on the outer membrane of the Borrelia cell wall that is known to be proinflammatory. These lipoproteins attract neutrophils and have shown to be 50- to 500-fold more active inducers of cytokines and mitogens of B cells than lipoproteins of other organisms, such as Escherichia coli. Bacterial & Borrelia lipoproteins can disseminate from the periphery to inflame the brain [43].

There are some other immune pathological processes associated with Lyme disease. The neuropsychiatric Herxheimer reaction appears to be an adverse immune reaction to treatment although the exact mechanism is not well clarified [49]. In the phase II AN1792 trial of active antimyeloid beta immunization against AD, there were two patients fulfilling clinical AD criteria who were diagnosed with Lyme neuroborreliosis during screening who developed meningoencephalitis associated with destructive neuroinflammation apparently provoked by an interaction of the vaccine and the presence of Lyme neuroborreliosis [50]. The immune reactions seen in LYD/TBD are different from the immune reactions seen in chronic fatigue syndrome and this may partially be explained by the distinguishing cerebrospinal fluid protein complements that are seen in these patients when compared to healthy controls [51].

MOLECULAR MIMICRY/AUTOIMMUNE MEDIATED MECHANISMS

Paraneoplastic limbic encephalopathies and pediatric autoimmune diseases associated with strep (PANDAS) are good models to understand the effects of autoantibodies directed against intracellular neuronal antigens and the associated psychiatric symptoms. In paraneoplastic and nonparaneoplastic limbic encephalitis, voltage-gated potassium channel limbic encephalitis, Hashimoto’s encephalopathy, anti-NMDA and other glutamate receptor encephalitis, encephalitis associated with gamma-aminobutyric acid signaling and systemic lupus erythematosus neurons are excited to death by autoantibodies resulting in neurotoxicity [52,53]. PANDAS is an interaction of a Streptococcal infection in a genetically susceptible individual at a young age which can result in obsessive compulsive disorder, tics and sometimes attention span difficulties. PANDAS is often comorbid with LYD/TBD and the broader categorization has been referred to as pediatric infection-triggered autoimmune neuropsychiatric disorders. Symptom flares follow a strep infection and correlate with increased antibody production [54-56]. Lyme surface antigens can cause molecular mimicry and associated autoimmune symptoms. Bb spirochetes surface glycolipids may elicit cross-reactive antibodies and IgM Bb flagella antibodies cross-reacted with neuronal antigens [43]. Anti-neural antibody reactivity has been demonstrated in patients with a history of Lyme borreliosis and persistent symptoms. Anti-neural antibody reactivity was found to be significantly higher in the Lyme patients with prior treatment...
and persistent symptoms (PLS) group than in the post-Lyme healthy and normal healthy groups [57]. Immunohistochemical analysis of PLS serum antibody activity demonstrated binding to cells in the central and peripheral nervous systems. The presence of anti-neural antibody reactivity in patients with PLS demonstrates ‘objective immunologic abnormalities’ and underscores the pathophysiologic nature of PLS and discredits the psychosomatic theory advanced by some as the cause of persisting symptoms [58]. Since immunologic abnormalities can be caused by an ongoing infectious process, a growing list of animal and human studies suggest that persistent infection is required for the production of autoantibodies such as the anti-neural antibodies described by Chandra and colleagues; it is likely that persistent infection with the Lyme spirochete Bb may be driving production of these antibodies [59].

**CHRONIC INFECTIONS, LYME/TICK-BORNE DISEASE, IMMUNE EFFECTS AND AUTISM SPECTRUM DISORDER**

There has been recent attention to the association between chronic infections, LYD/TBD and autism spectrum disorders (ASD). Immune reactivity associated with these infections in the mother, fetus and child appear to adversely affect developing neural tissue and contribute to the pathophysiology associated with autism spectrum disorders. Possible pathophysiological mechanisms include both inflammatory processes as well as autoantibodies to developing neural tissue [5,6,60,61].

During postnatal life, an intact BBB limits the entry of immune species into the brain. Lymphocytes, macrophages, various cytokines, and antibodies are generally maintained in the periphery. However, the blood–brain barrier is permeable during fetal development and can be compromised by infections and environmental exposures throughout life. The absence of a complete barrier allows immune components access to the brain. Individuals with autism show increased pro-inflammatory cytokines in the brain, as well as activation of microglia. Additionally, antibodies that target brain tissues have been described in both children with autism and their mothers. These immunological phenomena may interfere with normal brain development and function, potentially contributing to the development and/or symptoms of ASD [62].

One mouse model for cytokine mediated effects associated with ASD is demonstrated by maternal injection of IL-6 at different gestational stages is associated with different deficits associated with ASD [63]. Autoantibodies targeting brain proteins have been discovered in both children with autism and their mothers and circulating maternal autoantibodies directed toward fetal brain proteins are highly specific for autism. Additionally, data suggest there may be a defect in signaling pathways that are shared by the immune and central nervous systems. One model of autoimmune mediated effects associated with ASD is demonstrated by exposing rhesus monkeys to IgG from mothers of children with autism which results in the appearance of ASD symptoms [64]. In addition, antibodies that react to the 36, 37, 39, 61 and/or 73 kDa bands on Western Blot testing are associated with provoking an immune reaction and contribute to causing autism. Reactivity to these bands is also associated with Borrelia burgdorferi and to a lesser degree to Bartonella henselae, Bartonella quintana, Mycoplasma, Chlamydia pneumonia and Streptococcus pneumoniae [5].

**CONCLUSION**

When looking at the clinical and basic science research on the subject articles it is apparent that persistent infection and associated inflammation and molecular mimicry mechanisms are associated with gradually increasing encephalopathy and gradually increasing mental symptoms. Cognitive symptoms begin as executive dysfunction and mild cognitive impairments and may gradually progress to dementia while emotional symptoms begin with insomnia, reduced frustration tolerance, irritability and dysthymia and may progress to anxiety disorders, depression, impulsivity and personality disorders and subsequently psychosis and/or suicidal and homicidal tendencies. Many of the neurological, cognitive and psychiatric symptoms associated with LYD/TBD appear to be mediated by immune mechanisms. Therefore greater interaction is needed between infectious disease specialists, immunologists and mental health practitioners.

**LIST OF ABBREVIATIONS**

| Abbreviation | Description |
|--------------|-------------|
| CNS          | Central nervous system |
| IL           | Interleukin |
| TNF          | Tumor necrosis factor |
| AD           | Alzheimer’s disease |
| BBB          | Blood brain barrier |
| NMDA         | N-Methyl-D-aspartic acid |
| IDO          | Indoleamine 2,3-dioxygenase |
| PANDAS       | Pediatric autoimmune diseases associated with strep |
| PLS          | LYME patients with prior treatment and persistent symptoms |
| ASD          | Autism spectrum disorders |

**CONFLICT OF INTEREST**

The authors confirm that this article content has no conflicts of interest.

**ACKNOWLEDGEMENTS**

None declared.

**REFERENCES**

[1] Miklossy J. Alzheimer’s disease - a neurospirochetosis. analysis of the evidence following Koch’s and Hill’s criteria. J Neuroinflammation 2011; 8: 90.

[2] Brown AS, Patterson PH. Maternal infection and schizophrenia: implications for prevention. Schizophr Bull 2011; 37: 284-90.

[3] Ling VJ, Lester D, Mortensen PB, Langenberg PW, Postolache TT. Toxoplasma gondii seropositivity and suicide rates in women. J Nerv Ment Dis 2011; 199:440-4.
effects of inorganic and organic mercury species
oxide production in wake-active ba sal forebrain neurons. J Neuro-
Kalinchuk AV, McCarley RW, Porkka-Heiskanen T, Basheer R.

Daneman R, Rescigno M. The gut immune barrier and the blood-
304.

Dowlati Y, Herrmann N, Swardfager W, 

Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology
immune response. Ann N Y Acad Sci. 1990; 594: 95-103.

Kelley KW. The role of growth hormone in modulation of the
brain barrier: are they so different? Immunity 2009; 31: 722-35.

Daneman R, Rescigno M. The gut immune barrier and the blood-
barrier: are they so different? Immunity 2009; 31: 722-35.

Kalinchuk AV, McCarley RW, Porkka-Heiskanen T, Basheer R.

Daneman R, Rescigno M. The gut immune barrier and the blood-

Dowlati Y, Herrmann N, Swardfager W, 

Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology
immune response. Ann N Y Acad Sci. 1990; 594: 95-103.

Kelley KW. The role of growth hormone in modulation of the
brain barrier: are they so different? Immunity 2009; 31: 722-35.

Daneman R, Rescigno M. The gut immune barrier and the blood-

Dowlati Y, Herrmann N, Swardfager W, 

Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology
immune response. Ann N Y Acad Sci. 1990; 594: 95-103.

Kelley KW. The role of growth hormone in modulation of the
brain barrier: are they so different? Immunity 2009; 31: 722-35.

Daneman R, Rescigno M. The gut immune barrier and the blood-

Dowlati Y, Herrmann N, Swardfager W, 

Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology
immune response. Ann N Y Acad Sci. 1990; 594: 95-103.

Kelley KW. The role of growth hormone in modulation of the
brain barrier: are they so different? Immunity 2009; 31: 722-35.

Daneman R, Rescigno M. The gut immune barrier and the blood-

Dowlati Y, Herrmann N, Swardfager W, 

Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology
immune response. Ann N Y Acad Sci. 1990; 594: 95-103.

Kelley KW. The role of growth hormone in modulation of the
brain barrier: are they so different? Immunity 2009; 31: 722-35.

Daneman R, Rescigno M. The gut immune barrier and the blood-

Dowlati Y, Herrmann N, Swardfager W, 

Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology
immune response. Ann N Y Acad Sci. 1990; 594: 95-103.

Kelley KW. The role of growth hormone in modulation of the
brain barrier: are they so different? Immunity 2009; 31: 722-35.

Daneman R, Rescigno M. The gut immune barrier and the blood-

Dowlati Y, Herrmann N, Swardfager W, 

Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology
immune response. Ann N Y Acad Sci. 1990; 594: 95-103.

Kelley KW. The role of growth hormone in modulation of the
brain barrier: are they so different? Immunity 2009; 31: 722-35.

Daneman R, Rescigno M. The gut immune barrier and the blood-

Dowlati Y, Herrmann N, Swardfager W, 

Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology
immune response. Ann N Y Acad Sci. 1990; 594: 95-103.

Kelley KW. The role of growth hormone in modulation of the
brain barrier: are they so different? Immunity 2009; 31: 722-35.

Daneman R, Rescigno M. The gut immune barrier and the blood-

Dowlati Y, Herrmann N, Swardfager W, 

Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology
immune response. Ann N Y Acad Sci. 1990; 594: 95-103.

Kelley KW. The role of growth hormone in modulation of the
brain barrier: are they so different? Immunity 2009; 31: 722-35.

Daneman R, Rescigno M. The gut immune barrier and the blood-

Dowlati Y, Herrmann N, Swardfager W, 

Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology
immune response. Ann N Y Acad Sci. 1990; 594: 95-103.

Kelley KW. The role of growth hormone in modulation of the
brain barrier: are they so different? Immunity 2009; 31: 722-35.

Daneman R, Rescigno M. The gut immune barrier and the blood-

Dowlati Y, Herrmann N, Swardfager W, 

Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology
immune response. Ann N Y Acad Sci. 1990; 594: 95-103.

Kelley KW. The role of growth hormone in modulation of the
brain barrier: are they so different? Immunity 2009; 31: 722-35.

Daneman R, Rescigno M. The gut immune barrier and the blood-

Dowlati Y, Herrmann N, Swardfager W, 

Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology
immune response. Ann N Y Acad Sci. 1990; 594: 95-103.

Kelley KW. The role of growth hormone in modulation of the
brain barrier: are they so different? Immunity 2009; 31: 722-35.
associated with streptococcal infection. Psychiatr Clin North Am 2002; 25: 1-16.

[55] Ercan TE, Ercan G, Severge B, Arpaozu M, Karasu G. Mycoplasma pneumoniae infection and obsessive-compulsive disease: a case report. J Child Neurol 2008; 23: 338-40.

[56] Leah E. Neuropsychiatric disorders: Neurons excited to death by SLE autoantibodies. Nat Rev Rheumatol 2011; 7: 1.

[57] Chandra A, Wormser GP, Klempner MS, et al. Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms. Brain Behav Immun 2010; 24: 1018-24.

[58] Hassett AL, Radvanski DC, Buyske S, Savage SV, Sigal LH. Psychiatric comorbidity and other psychological factors in patients with chronic Lyme disease. Am J Med 2009; 122: 843-50.

[59] Stricker RB, Johnson L. Letter to the editor re "Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms" by Chandra et al. Brain Behav Immun. 2010; 24:1025; author reply 1026.

[60] Nicolson GL, Gan R, Nicolson NL, Haier J. Evidence for Mycoplasma, Chlamydia pneumoniae and HHV-6 co-infections in the blood of patients with autism spectrum disorders. J Neurosci Res 2007; 85: 1143-8.

[61] Nicholson G. Chronic bacterial and viral infections in neurodegenerative and neurobehavioral diseases. Lab Med 2008; 39: 291-9

[62] Goines P, Van de Water J. The immune system's role in the biology of autism. Curr Opin Neurol 2010; 23: 111-7.

[63] Smith SE, Li J, Garbett K, Mimics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007; 27: 10695-702.

[64] Martin LA, Ashwood P, Braunschweig D, Cabanlit M, Van de Water J, Amaral DG. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav Immun 2008; 22: 806-16.